In conclusion, this work has identified five metabolites capable of discriminating PDAC and CP in blood either as single or as a panel of markers. Findings were validated in a separate patient cohort. To determine the potential clinical benefit of these markers, further evaluation in larger clinical studies is needed. Nevertheless, we believe that these metabolites are potentially useful for early diagnosis of PDAC in CP patients.